Soligenix Reports Positive Phase 2a Results for Psoriasis Treatment SGX302 Gel Therapy

Soligenix Advances Psoriasis Treatment with Promising Phase 2a Trial Results

Soligenix, Inc. announces positive outcomes from the third cohort of its Phase 2a clinical trial for SGX302, a synthetic hypericin-based treatment targeting mild-to-moderate psoriasis. This trial, which focuses on enhancing patient experience through an optimized gel formulation, includes four additional patients who benefit from a product designed for easier application over larger skin areas. Conducted over an 18-week period, the trial reveals that the SGX302 gel therapy is well tolerated, showing no drug-related adverse events. Among the three evaluable patients, significant improvements in clinical measures are noted, including the Investigator Global Assessment (IGA) and the Psoriasis Activity and Severity Index (PASI).

The results highlight the efficacy of the gel formulation, with one patient achieving an "Almost Clear" status on the IGA and a PASI improvement exceeding 50%. These findings are either on par with or surpass those from earlier trials with the ointment formulation, reinforcing the gel's enhanced application characteristics. This step forward confirms SGX302's potential in ameliorating psoriasis lesions, aligning with the success seen in photodynamic therapies and offering a non-carcinogenic, non-mutagenic treatment alternative for severe lesions. The encouraging data marks a significant milestone for Soligenix as it seeks to address the substantial unmet medical needs in the field of dermatology.

CEO Christopher J. Schaber expresses satisfaction with these preliminary findings, emphasizing that the gel's design not only improves patient experience but also fits into the company's broader strategy. This strategy involves exploring synthetic hypericin's applications in additional disease indications, targeting areas where current treatments fall short. With an estimated 60-125 million people affected by psoriasis worldwide and a treatment market projected to grow from $15 billion in 2020 to $40 billion by 2027, Soligenix is strategically positioned to make a meaningful impact in this growing sector.

In parallel, the company continues to focus on its commitment to rare diseases, which reflects both a strong market demand and a dedication to addressing niche medical challenges. The ongoing development of SGX302 and its potential applications underscore Soligenix's innovative approach in a competitive biopharmaceutical landscape. As the company progresses through clinical trials, it remains dedicated to enhancing the lives of patients suffering from chronic conditions, demonstrating a proactive stance in the fight against psoriasis and other rare diseases.